AR083757A1 - Derivados heterociclicos nitrogenados de imidazo-pirrolidinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por hcv - Google Patents
Derivados heterociclicos nitrogenados de imidazo-pirrolidinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por hcvInfo
- Publication number
- AR083757A1 AR083757A1 ARP110104114A ARP110104114A AR083757A1 AR 083757 A1 AR083757 A1 AR 083757A1 AR P110104114 A ARP110104114 A AR P110104114A AR P110104114 A ARP110104114 A AR P110104114A AR 083757 A1 AR083757 A1 AR 083757A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- optionally substituted
- independently
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical class [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 33
- 229910052739 hydrogen Inorganic materials 0.000 abstract 19
- 239000001257 hydrogen Substances 0.000 abstract 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 11
- 229910052799 carbon Inorganic materials 0.000 abstract 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 8
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 150000001721 carbon Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- -1 -CH2-heteroaryl Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41026710P | 2010-11-04 | 2010-11-04 | |
| US201161444046P | 2011-02-17 | 2011-02-17 | |
| US201161492267P | 2011-06-01 | 2011-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083757A1 true AR083757A1 (es) | 2013-03-20 |
Family
ID=44993923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104114A AR083757A1 (es) | 2010-11-04 | 2011-11-04 | Derivados heterociclicos nitrogenados de imidazo-pirrolidinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por hcv |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8921372B2 (enExample) |
| EP (1) | EP2635571B1 (enExample) |
| JP (1) | JP5891235B2 (enExample) |
| CN (1) | CN103189371B (enExample) |
| AR (1) | AR083757A1 (enExample) |
| CA (1) | CA2814534A1 (enExample) |
| ES (1) | ES2548286T3 (enExample) |
| TW (1) | TW201249827A (enExample) |
| WO (1) | WO2012061552A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2473414C2 (ru) * | 2007-06-12 | 2013-01-27 | ТЕКНОЛАЙНЗ, ЭлЭлСи | Способы и системы высокоскоростной и высокомощной лазерной гравировки |
| EA020031B1 (ru) * | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8921372B2 (en) * | 2010-11-04 | 2014-12-30 | Theravance Biopharma R&D Ip, Llc | Inhibitors of hepatitis C virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9273043B2 (en) | 2011-06-22 | 2016-03-01 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
| KR20140091036A (ko) * | 2011-11-03 | 2014-07-18 | 세라밴스 인코포레이티드 | 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제 |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| HUE032173T2 (en) | 2012-04-25 | 2017-09-28 | Theravance Biopharma R&D Ip Llc | Piperazine piperidine compounds as inhibitors of hepatitis C virus |
| CA2869908C (en) | 2012-04-25 | 2018-02-20 | Theravance Biopharma R&D Ip, Llc | Hepatitis c virus inhibitors |
| US8883135B2 (en) | 2012-05-03 | 2014-11-11 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN105175401A (zh) * | 2015-10-16 | 2015-12-23 | 北京康立生医药技术开发有限公司 | 一种依匹哌唑的制备方法 |
| CN107814789B8 (zh) * | 2017-11-27 | 2021-01-01 | 常州寅盛药业有限公司 | 一种达卡他韦起始原料的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0421908D0 (en) * | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| AU2006290442B2 (en) * | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101558059B (zh) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US7910722B2 (en) * | 2007-07-05 | 2011-03-22 | Florida State University Research Foundation | RNAi therapeutic for treatment of hepatitis C infection |
| HRP20120440T1 (hr) | 2008-02-12 | 2012-06-30 | Bristol-Myers Squibb Company | Inhibitori virusa hepatitisa c |
| EP2774927A1 (en) | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2010094977A1 (en) * | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8921372B2 (en) * | 2010-11-04 | 2014-12-30 | Theravance Biopharma R&D Ip, Llc | Inhibitors of hepatitis C virus |
| KR20140091036A (ko) | 2011-11-03 | 2014-07-18 | 세라밴스 인코포레이티드 | 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제 |
-
2011
- 2011-11-03 US US13/288,216 patent/US8921372B2/en not_active Expired - Fee Related
- 2011-11-03 ES ES11784875.4T patent/ES2548286T3/es active Active
- 2011-11-03 EP EP11784875.4A patent/EP2635571B1/en active Active
- 2011-11-03 CN CN201180053127.4A patent/CN103189371B/zh not_active Expired - Fee Related
- 2011-11-03 WO PCT/US2011/059061 patent/WO2012061552A1/en not_active Ceased
- 2011-11-03 JP JP2013537808A patent/JP5891235B2/ja not_active Expired - Fee Related
- 2011-11-03 CA CA2814534A patent/CA2814534A1/en not_active Abandoned
- 2011-11-04 AR ARP110104114A patent/AR083757A1/es not_active Application Discontinuation
- 2011-11-04 TW TW100140412A patent/TW201249827A/zh unknown
-
2014
- 2014-11-12 US US14/539,039 patent/US9260414B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120114600A1 (en) | 2012-05-10 |
| CA2814534A1 (en) | 2012-05-10 |
| CN103189371B (zh) | 2015-04-01 |
| WO2012061552A1 (en) | 2012-05-10 |
| CN103189371A (zh) | 2013-07-03 |
| US9260414B2 (en) | 2016-02-16 |
| US20150071878A1 (en) | 2015-03-12 |
| US8921372B2 (en) | 2014-12-30 |
| JP5891235B2 (ja) | 2016-03-22 |
| JP2013544812A (ja) | 2013-12-19 |
| TW201249827A (en) | 2012-12-16 |
| EP2635571B1 (en) | 2015-08-12 |
| EP2635571A1 (en) | 2013-09-11 |
| ES2548286T3 (es) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113895A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
| MX2022003276A (es) | Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg. | |
| AR088630A1 (es) | Inhibidores del virus de la hepatitis c | |
| ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| ES2259113T3 (es) | Inhibidores del factor xa y de otras serinproteasas implicadas en la cascada de coagulacion. | |
| AR101051A1 (es) | Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos | |
| RU2012108629A (ru) | Фенилэтинильные производные в качестве ингибиторов вируса гепатита с | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
| RU2012112824A (ru) | Производные бис-бензимидазола | |
| AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
| AR073586A1 (es) | Compuestos heterociclicos utiles para el tratamiento de vhc | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR073450A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AR090836A1 (es) | Derivados de benzamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |